evipedia.ai
← Back

Thymulin for Health & Longevity

Evidence Review created on 10/26/2026 using AI4L / Opus 5.5

Also known as: Facteur Thymique Sérique, FTS, Serum Thymic Factor, Zinc-Thymulin, FTS-Zn, Nonathymulin, Thymulin Acetate

Motivation

Thymulin is a small hormone made by the thymus, the gland behind the breastbone where key immune cells mature. It only works when paired with zinc, and its levels in the blood fall from early adulthood as the thymus itself shrinks. That decline has made it a candidate for people seeking to keep the immune system youthful with age.

Thymulin was discovered in France in the 1970s and tested as an injected drug in small studies in the 1980s, after which interest faded. It has drawn renewed attention since recent animal research examined whether its loss with age contributes to the low-grade, persistent inflammation of later life, and it is now sold online as an unapproved research chemical.

This review examines what is known about injected thymulin and about raising the body’s own thymulin through zinc: the evidence on immune function, inflammation and related outcomes, the safety record, sourcing and legal status, and the open questions that remain for health-focused adults considering it.

Benefits - Risks - Protocol - Conclusion

This section lists overview articles and narrative reviews on thymulin from longevity-focused writers and thymus researchers.

Only three items are listed because no further overview content discusses thymulin in depth. Rhonda Patrick covers thymulin only in one paragraph of her zinc overview (FoundMyFitness: Zinc), Peter Attia mentions it only in passing, in a sentence on the TRIIM trial (Peter Attia: Can you reverse your biological age?), and Life Extension Magazine only in a sentence on its zinc dependence in a 1999 article (Life Extension Magazine: Staying Young Forever). No relevant content was found from Andrew Huberman (hubermanlab.com) or Chris Kresser (chriskresser.com): both sites’ own searches returned no thymulin content, and web searches surfaced none.

Grokipedia

Thymulin

AI-generated encyclopedia entry covering thymulin’s discovery, structure, zinc dependence, neuroendocrine roles and research directions; useful for orientation, though its claims need checking against the primary studies.

Examine

No Examine article on thymulin exists.

ConsumerLab

No ConsumerLab article on thymulin exists.

Systematic Reviews

No systematic reviews or meta-analyses for Thymulin were found on PubMed as of October 26, 2026.

Mechanism of Action

Thymulin is a nine-amino-acid peptide (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) made by thymic epithelial cells, the thymus’s supporting cells. It is active only when bound to one zinc ion; the zinc-free peptide, FTS (facteur thymique sérique), circulates but is inert (Dardenne 1994).

  • Immune maturation: The synthetic peptide (FTS) binds high-affinity receptors on certain subsets of T cells (immune cells that mature in the thymus) (Pléau 1980); thymulin promotes T-cell differentiation (Dardenne 1994), and restored the activity of NK cells (natural killer cells, innate immune cells that destroy infected or cancerous cells) from old mice in vitro (in lab cultures) (Muzzioli 1992).
  • Anti-inflammatory signaling: It reduces IL-1, IL-6 and TNF-α (interleukin-1, interleukin-6 and tumor necrosis factor-alpha, signaling proteins that drive inflammation) by inhibiting NF-κB (nuclear factor kappa B, a master switch for inflammatory genes) and p38 MAPK (a stress-activated signaling enzyme) (Kanemaru 2026; Nasseri 2019).
  • Pituitary cross-talk: In rat pituitary cells it releases growth hormone, less so in cells from old rats (Brown 1999).

Explanations of its age-related decline compete: adding zinc to plasma from people over 50 restored activity, implicating zinc shortage rather than thymic failure (Fabris 1984); others attribute the fall to thymic involution (age-related shrinkage of the thymus) (Consolini 2000).

Pharmacology: Human half-life, tissue distribution and metabolism are unmeasured. Binding is selective for certain T-cell lines, not B cells (antibody-producing immune cells) (Pléau 1980). It is presumably cleared by peptidases (protein-cutting enzymes), not CYP450 (liver drug-metabolizing) enzymes; degradation-resistant analogues exist because the native peptide breaks down quickly (Kaiserlian 1981).

Historical Context & Evolution

Jean-François Bach and Mireille Dardenne in Paris identified a serum thymic factor in the early 1970s, later determined its sequence and showed that zinc confers its activity, renaming it thymulin (reviewed in Reggiani 2009 and Bach 1989). Its original intended use was as an immune-restoring hormone for thymus-deficient states: intravenous (into a vein) synthetic FTS improved cellular immunity and antibody production in three immunodeficient children (Bordigoni 1982). The synthetic peptide (nonathymulin) then entered placebo-controlled trials, which found clinical improvement in rheumatoid arthritis at 5 mg daily (Amor 1987) and no effect on disability in multiple sclerosis (Roullet 1989); the arthritis trials were co-authored by the peptide’s discoverers. No regulator approved it, and no further human trials were published.

Interest in health optimization grew from aging research. Thymulin activity is low in older adults and partly recoverable with zinc (Fabris 1984; Prasad 1993), and Argentine researchers used thymulin gene therapy to prevent reproductive and endocrine defects in thymus-deficient mice, a model of reproductive aging (Reggiani 2012). In 2026, a study found that thymulin restrains age-associated inflammation in old mice (Kanemaru 2026), reviving attention, and the peptide now circulates in online research-peptide markets.

Opinion shifted with the evidence rather than settling: the 1980s human trials were small and were neither replicated nor refuted by larger studies, and the newer, longevity-relevant signals come from animals. The standing of the early human findings therefore remains open.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: each human finding comes from a single research group or an uncontrolled case series, and the longevity-relevant signals rest on mouse and cell-culture studies.

Medium 🟩 🟩

Reduced Rheumatoid Arthritis Activity ⭕️ Not Central to Health & Longevity

This benefit bears on rheumatoid arthritis, not on healthy aging. Two randomized, double-blind, placebo-controlled trials from one Paris group compared synthetic thymulin (nonathymulin) at 1, 5 and 10 mg daily; 5 mg was most effective, improving global assessment and four objective measures with minimal adverse effects (Amor 1987). Thymulin’s discoverers, Bach and Dardenne, co-authored the trials. Responses correlated with T-cell subset imbalance, and no other group has replicated the finding.

Magnitude: Global improvement in 56% of patients on 5 mg daily versus 17% on placebo (p<0.02, meaning a difference this large would arise by chance less than 2% of the time if the drug had no effect); no confidence interval (range of plausible true effects) reported (Amor 1987).

Low 🟩

Immune Recovery in T-Cell Deficiency

In an uncontrolled series of three children with T-cell defects and missing or low IgA (immunoglobulin A, the antibody guarding mucous membranes), intravenous synthetic thymulin reduced infections and restored IgA and vaccine antibodies; gains regressed during pauses (Bordigoni 1982). Relevance to age-related immune decline is untested.

Magnitude: Serum IgA, previously absent in two of three patients, appeared within 4 weeks of treatment; no control group (Bordigoni 1982).

Speculative 🟨

Restored Thymulin Activity with Zinc Repletion ⚠️ Conflicted

Indirect: zinc reactivates endogenous thymulin rather than supplying it. Serum thymulin activity, an unvalidated biomarker, rose in zinc-deficient older adults (Prasad 1993), not in placebo-controlled Gambian children (Bates 1993). Net: effects appear confined to deficiency.

In aged mice and lab-grown blood cells from older people, thymulin suppressed inflammatory signaling proteins via NF-κB, without effect in young mice (Kanemaru 2026). Mechanistic and animal data only.

Better Tumor Control in Older Animals

Thymulin slowed tumor growth, improved survival and sensitized tumors to anti-PD-L1 immunotherapy (drugs blocking a protein tumors use to switch off T cells) in aged, not young, mice (Kanemaru 2026). Animal data only.

Pain Relief ⭕️ Not Central to Health & Longevity

This bears on pain, not aging. Thymulin reduced inflammatory pain and swelling in rats (Nasseri 2019), and an analogue matched morphine against nerve-injury pain (Saadé 2003; inventors of expired US patent 7,309,690). Animal data only.

Protection of Allergic Airways ⭕️ Not Central to Health & Longevity

This bears on asthma. Inhaled nanoparticles carrying the thymulin gene reversed airway inflammation and scarring in mouse asthma models (da Silva 2020); gene delivery differs from peptide injection. Animal data only.

Preserved Neuroendocrine and Reproductive Function

In nude (thymus-lacking) mice, neonatal gene therapy encoding a thymulin analogue prevented faulty ovary development and eased reproductive hormone defects (Reggiani 2012; review: Reggiani 2011). Gene delivery, not peptide injection; animal data only.

Organ Protection from Toxic Drugs ⭕️ Not Central to Health & Longevity

This bears on drug toxicity. Thymulin reduced cisplatin (a chemotherapy drug) kidney damage in rats (Kohda 2005) and lung scarring from bleomycin (another chemotherapy drug) in mice (Yara 2001; Mitsui Pharmaceuticals co-affiliated). Animal only.

Oxidative-Stress Markers in Accelerated Aging

In senescence-accelerated mice, repeated thymulin raised antioxidant enzyme activity and lowered a lipid-damage marker in brain and kidney (Zhao 1990). These biomarkers are unvalidated for human aging; animal data only.

Benefit-Modifying Factors

  • Zinc status: Thymulin is inactive without zinc; mild deficiency lowers its activity and repletion restores it (Prasad 1988). In a controlled trial in Gambian children, zinc did not raise thymulin (Bates 1993), suggesting the effect is confined to deficiency.
  • Age: Thymulin peaks at ages 5–10 and reaches its lowest level by about 36 (Consolini 2000). In mice, anti-inflammatory and tumor effects appeared only in old animals (Kanemaru 2026), making older adults the plausible responders.
  • Sex: No human study has reported sex differences in response. Thymulin gene therapy corrected ovarian development in female mice (Reggiani 2012), but no male–female comparison exists.
  • Genetic polymorphisms: No gene variant is known to modify thymulin’s benefits; no trial has examined genotype.
  • Baseline biomarkers: Low zinc and elevated inflammatory signaling define the settings in which effects appeared (Prasad 1993; Kanemaru 2026); in rheumatoid arthritis, response correlated with T-cell subset imbalance (Amor 1987).
  • Pre-existing conditions: Thymulin activity is low in anorexia nervosa (Wade 1985) and Down syndrome (Fabris 1984); the multiple sclerosis trial found no benefit (Roullet 1989).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the controlled human trials report no harms with event rates, and the specific concerns rest on rodent, cell-culture, zinc case-report or indirect product-quality data.

Medium 🟥 🟥

No risk reaches Medium: no controlled human study has documented an adverse event attributable to thymulin; the evidence below is qualitative trial reporting, zinc case reports, indirect product testing or animal work.

Low 🟥

Mild Adverse Events at Trial Doses ⚠️ Conflicted

Placebo-controlled trials from two independent groups, Amor in rheumatoid arthritis (Amor 1987) and Roullet in multiple sclerosis (40 patients, 6 months) (Roullet 1989), reported minimal or no significant side effects, without event rates. Net: no excess harm was seen, but small trials could miss uncommon adverse events.

Magnitude: Not quantified in available studies. The trial abstracts describe adverse effects only as “minimal” or not significant and give no event rates for either the thymulin or the placebo group.

Contaminated or Mislabeled Products

Thymulin is sold only as an unregulated research chemical. Indirect evidence from a different peptide: semaglutide (a weight-loss drug) vials bought online showed purity far below the labeled 99%, and all carried endotoxin (bacterial debris that can cause fever) (Ashraf 2024). No thymulin-specific testing exists.

Magnitude: In three vials of a different peptide bought online, measured purity was 7.7%–14.37% against a labeled 99%, and endotoxin was detected in all three; no control group (Ashraf 2024).

Copper Deficiency from Excess Zinc

Protocols pair thymulin with zinc, and long-term excess zinc disrupts copper metabolism, causing anemia and low white-cell counts. A systematic review of 37 published cases, commonly from supplements, found low serum copper in every patient; most recovered after stopping zinc and adding copper (Dutta 2026). Evidence is case reports only.

Magnitude: Reported daily elemental zinc intakes ranged from about 50 mg to more than 1,500 mg over weeks to years; anemia was present in nearly all 37 cases and serum copper was low in all; no control group (Dutta 2026).

Speculative 🟨

Paradoxical Pain Sensitization

At nanogram doses, thymulin caused hyperalgesia (heightened pain sensitivity) in rodents via prostaglandins (inflammatory messengers), the opposite of its higher-dose pain relief, as a review summarizes (Dardenne 2006). Animal data only.

Immune Suppression

Synthetic thymulin delayed skin-graft rejection in mice, an immunosuppressive effect (Kaiserlian 1981), raising a theoretical concern for weaker responses to infection. Animal data only; no human infection signal reported.

Pituitary Hormone Release

In rat pituitary cells, thymulin stimulated prolactin and TSH (thyroid-stimulating hormone) release (Brown 1998). Whether injected thymulin raises these hormones in humans is unknown; cell-culture data only.

Risk-Modifying Factors

  • Genetic polymorphisms: No gene variant is known to alter thymulin’s side effects; no pharmacogenetic study exists.
  • Baseline biomarkers: Elevated prolactin or TSH at baseline would compound the pituitary stimulation seen in rat cells (Brown 1998); low baseline copper leaves less margin against the copper depletion and anemia that excess zinc caused in a systematic review of case reports (Dutta 2026).
  • Sex: No sex differences in side effects are reported. Women who may become pregnant face unknown reproductive risk, given thymulin’s effects on ovarian development in mice (Reggiani 2012).
  • Pre-existing conditions: Pituitary disorders, organ transplantation, immunosuppressive treatment (drugs that dampen immune activity) and cancer immunotherapy add uncertainty because thymulin modulates pituitary hormones (Brown 1998) and immunity (Kaiserlian 1981) in animals.
  • Age: Older adults, the main users, are more likely to take interacting drugs and high-dose zinc; no trial enrolled healthy older adults, so tolerability in this group is unstudied.

Key Interactions & Contraindications

Documented interactions:

  • Zinc supplements: Potentiating in deficiency: repletion restored serum thymulin in zinc-deficient adults (Prasad 1988); a placebo-controlled trial in Gambian children found no effect (Bates 1993). Excess zinc causes copper-deficiency anemia, per a systematic review of case reports (Dutta 2026); repletion is limited to documented deficiency.
  • Mercury exposure: Dental staff occupationally exposed to amalgam mercury vapor had lower blood thymulin than controls (Farahat 2009); consequence is reduced endogenous thymulin. Workplace hygiene limits exposure.
  • Cyclosporine: In kidney-transplant patients, cyclosporine infusion further lowered already low serum thymulin, which recovered within two weeks (Togni 1990); consequence is reduced endogenous thymulin activity. Mitigation: combination only with the transplant specialist’s knowledge.
  • Bromocriptine: In patients with prolactin-secreting pituitary tumors, 9 months of bromocriptine lowered prolactin and raised zinc and serum thymulin (Travaglini 1991); consequence is possibly higher thymulin activity. Prolactin testing tracks the combined effect.
  • Recombinant growth hormone (somatropin): In children and adults with growth hormone deficiency, 6 months of somatropin restored low active thymulin to control levels (Mocchegiani 1996); consequence is possibly higher thymulin activity. Mitigation: combination only with the prescribing physician’s knowledge.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Immunosuppressants (prednisone, tacrolimus, adalimumab): Inferred from thymulin’s immunosuppressive effect on mouse skin grafts; consequence is unpredictable additive or opposing immune modulation. Mitigation: combination only with the prescribing specialist’s knowledge.
  • Immune checkpoint inhibitors (cancer drugs that release immune brakes: pembrolizumab, nivolumab, atezolizumab): Inferred from enhanced anti-PD-L1 effects in aged mice; consequence could be amplified immune-related adverse events (immune attacks on healthy organs). Mitigation: oncologist oversight.
  • Prolactin-raising drugs (risperidone, haloperidol, metoclopramide): Inferred from thymulin-induced prolactin release in rat pituitary cells; consequence is additive prolactin elevation. Prolactin testing detects it.
  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen): Inferred from shared prostaglandin and inflammatory pathways; consequence is additive anti-inflammatory and pain-relieving effect. No mitigation needed beyond usual NSAID precautions.
  • Zinc chelators (agents that bind and remove metals: penicillamine, EDTA (ethylenediaminetetraacetic acid, a metal-binding agent), chelation therapy): Inferred from thymulin’s zinc dependence; consequence is inactivation of thymulin by zinc removal. Mitigation: avoiding the combination.
  • Immune-active supplements (thymosin alpha-1, thymalin, melatonin, arginine): Inferred from additive immune and thymus-restoring effects in rodents, reviewed in Mocchegiani 2006; consequence is stacked immune modulation of unknown net effect. Mitigation: introducing one agent at a time.
  • Vaccines (influenza, pneumococcal, shingles vaccines): Inferred from thymulin’s modulation of T-cell and antibody responses; consequence could be altered vaccine response. Mitigation: no regimen changes around vaccination.

Populations who should avoid Thymulin:

  • Athletes subject to anti-doping rules: WADA (World Anti-Doping Agency) prohibits non-approved substances (category S0) at all times (WADA Prohibited List); thymulin has no regulatory approval.
  • Pregnant or breastfeeding women: Inferred from thymulin’s effects on pituitary and ovarian development in mice (Reggiani 2012); no human data.
  • People with prolactin-secreting pituitary tumors or high prolactin: Inferred from prolactin release in rat pituitary cells (Brown 1998); no human data.
  • Organ transplant recipients on immunosuppression: Inferred from immune modulation in mouse graft studies (Kaiserlian 1981); no human data.
  • People on cancer immunotherapy outside a trial: Inferred from immunotherapy enhancement in aged mice (Kanemaru 2026); no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Third-party product analysis: Restricting use to batches with independent HPLC (high-performance liquid chromatography, a purity test), mass-spectrometry identity, endotoxin and sterility results mitigates the contamination and mislabeling documented for online-sourced peptides (Ashraf 2024).
  • Aseptic injection technique: Reconstitution with sterile bacteriostatic water, alcohol swabbing of vials and skin, and site rotation limit the infection risk added by non-sterile or endotoxin-contaminated research-grade products.
  • Zinc check before co-supplementing: Adding zinc only if plasma zinc is low prevents copper-deficiency anemia, reported from about 50 mg/day in a systematic review of case reports (Dutta 2026); copper is rechecked at 4–8 weeks, then every 3–6 months.
  • Pituitary hormone checks: Prolactin and TSH are tested at baseline and after 4–8 weeks, with use stopped if either exceeds the laboratory reference range; this mitigates the pituitary stimulation seen in rat cells.
  • Pain-sensitivity tracking: Stopping use when new, unexplained pain or tenderness appears mitigates the low-dose hyperalgesia seen in rodents.
  • Infection vigilance: Pausing use and seeking medical evaluation when infections become unusually frequent or prolonged mitigates possible immune suppression.
  • No unsupervised combination with immune drugs: Not pairing thymulin with immunosuppressants or checkpoint inhibitors without the treating specialist prevents unpredictable immune effects.
  • Time-limited courses: Courses within 6 months, the longest human exposure studied (Roullet 1989), limit exposure to unknown long-term effects.

Therapeutic Protocol

Doses below are cited to their source; other parameters without a citation (timing, cycle length, titration) reflect common practice.

  • Rheumatoid arthritis trial regimen: Nonathymulin 1, 5 or 10 mg daily, with 5 mg most effective (Amor 1987); this milligram range far exceeds the microgram doses used by telehealth clinics.
  • Multiple sclerosis trial regimen: Subcutaneous (under-the-skin) nonathymulin for 6 months (dose not stated in the abstract), without benefit on disability (Roullet 1989).
  • Telehealth protocol: 30–60 mcg subcutaneous daily in 20-day cycles separated by 10-day breaks, after confirming adequate zinc, per HealthRX, a commercial peptide seller (HealthRX thymulin page).
  • Popularizers: No prominent longevity physician has published a thymulin protocol; current use is driven by telehealth clinics such as HealthRX and online peptide vendors, whose doses are not trial-based.
  • Zinc as co-factor: Only zinc-bound thymulin is active (Dardenne 1994), so protocols pair it with dietary zinc and add supplemental zinc only for documented deficiency.
  • Time of day: No study has tested dosing time; morning and evening injections are both used in practice.
  • Half-life: Human half-life is unmeasured; analogues were developed because the native peptide degrades quickly (Kaiserlian 1981), suggesting brief exposure after each injection.
  • Single or split dosing: Trials used once-daily dosing (Amor 1987); split dosing has not been studied.
  • Genetic polymorphisms: No gene variant is known to affect thymulin dosing or response; no study has examined genotype.
  • Sex: No sex-specific dosing or response data exist; the trials did not report results by sex.
  • Age: Effects in mice appeared only in old animals (Kanemaru 2026); no trial has dosed healthy older adults, including those over 70.
  • Baseline biomarkers: Plasma zinc determines whether thymulin can be active; HealthRX requires zinc status to be confirmed before starting and links plasma zinc below 70 µg/dL to blunted activity (HealthRX thymulin page).
  • Pre-existing conditions: Human dosing experience exists only in autoimmune disease and immune deficiency; in rheumatoid arthritis, response tracked T-cell subset imbalance (Amor 1987).

Discontinuation & Cycling

  • Short-term or lifelong: Human use has not been studied beyond 6 months (Roullet 1989); thymulin is used in courses, not as lifelong therapy.
  • Withdrawal effects: No withdrawal syndrome is reported; in immunodeficient children, immune gains regressed when treatment paused and returned on restarting (Bordigoni 1982).
  • Tapering: No tapering protocol exists, and none appears necessary because no rebound effects are documented.
  • Cycling: Telehealth protocols use 20 days on and 10 days off (HealthRX thymulin page); no evidence shows that cycling preserves efficacy.

Sourcing and Quality

  • No approved product: No regulator has approved thymulin; reagent suppliers sell thymulin acetate labeled “not for human or veterinary use” (Cayman Chemical product page).
  • Zinc-free form: Products sold as thymulin acetate may contain the zinc-free nine-amino-acid peptide (FTS); zinc-free FTS stays inactive until zinc binds it, as adding zinc to human plasma showed (Fabris 1984).
  • Third-party testing: Quality markers are batch-specific HPLC purity of at least 98%, mass-spectrometry identity confirmation, and endotoxin and sterility results.
  • Compounding pharmacies: No compounding pharmacy has published independent identity, purity or sterility testing of thymulin, so none can be identified as a verified source; current supply comes from research-chemical vendors and telehealth clinics.
  • Name confusion: Thymulin differs from thymalin (a calf-thymus extract) and thymosin alpha-1 (a 28-amino-acid peptide); a label stating the nine-amino-acid sequence distinguishes it.
  • Storage: Powder is stored frozen or refrigerated; reconstituted solution is refrigerated and used within about 4 weeks.
  • Brands: No brand has published independent human-grade testing; no pharmacy or vendor can be identified as verified.

Practical Considerations

  • Time to effect: In immunodeficient children, IgA appeared within 4 weeks (Bordigoni 1982); the arthritis trials’ response timing is not reported in the abstract, and no data exist for healthy adults.
  • Common pitfalls: Confusing thymulin with thymalin or thymosin alpha-1, ignoring zinc status, extrapolating mouse findings to people, and assuming microgram vendor doses match the milligram trial doses.
  • Regulatory status: Not approved by the FDA (US Food and Drug Administration) or any other regulator; prohibited in tested sport under WADA S0 (WADA Prohibited List).
  • Access and cost: Available only from research-chemical vendors and some telehealth clinics, without insurance coverage; zinc repletion costs little. No company markets an approved product, so neither payers nor manufacturers have a financial incentive to fund larger trials.
  • Evidence vintage: All human trials date from 1982–1989 and used bioassays and reporting standards that differ from current practice.

Interaction with Foundational Habits

  • Sleep: Indirect: serum thymulin rises at night in humans, and in rats this rhythm depends on melatonin (Molinero 2000); in inflamed mice, thymulin partly restored brain melatonin (Novoselova 2018). No study has tested effects on sleep or dosing time.
  • Nutrition: Potentiating via zinc: zinc-rich foods (oysters, red meat, pumpkin seeds) support thymulin activity, while diets high in phytate (a plant compound in grains and legumes that binds zinc) reduce zinc absorption. Thymulin is low in anorexia nervosa, possibly from malnutrition (Wade 1985), but unchanged by a 3-week very-low-calorie diet (Bleiberg-Daniel 1992).
  • Exercise: None known: no study has examined thymulin with exercise, training adaptation or recovery, and no timing relative to workouts has been described.
  • Stress management: Indirect: in old mice, impaired thymulin activity coincided with high corticosterone, the rodent stress hormone (Mocchegiani 2004). Stress control plausibly supports endogenous thymulin, but no human data test this.

Monitoring Protocol & Defining Success

Baseline testing before starting covers zinc and copper status, a CBC (complete blood count) with differential, prolactin, TSH and hs-CRP (high-sensitivity C-reactive protein, a blood marker of inflammation). Each result either determines whether thymulin can act, flags a safety concern, or sets a reference point for change. Serum thymulin itself is measured only by research bioassays and is not commercially available, so success cannot be judged by the hormone level.

Ongoing monitoring repeats zinc, copper, prolactin and TSH at 4–8 weeks after starting, then every 3–6 months during continued use, with the CBC and hs-CRP rechecked every 3–6 months. A meaningful response would be fewer or shorter infections and a stable or falling hs-CRP, without abnormal pituitary hormones or blood counts.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Plasma zinc At least 70 µg/dL (HealthRX threshold) Safety and activity check: thymulin is inactive without zinc; guides zinc dosing Source: HealthRX thymulin page; conventional reference range about 60–120 µg/dL (varies by laboratory); morning fasting sample; pair with copper
Serum copper About 70–140 µg/dL (standard reference range) Safety check: detects zinc-induced copper deficiency Pair with zinc and CBC; low copper with anemia suggests zinc excess (systematic review of case reports: Dutta 2026)
CBC with differential Hemoglobin about 12.0–15.5 g/dL in women, 13.5–17.5 g/dL in men; white cells about 4,000–11,000/µL (standard reference range) Safety check: anemia or low white cells signal zinc excess or immune change Includes lymphocyte (white blood cells that include T and B cells) count; repeat if infections increase
Prolactin About 4–15 ng/mL in men, 4–23 ng/mL in women (standard reference range) Safety check: thymulin releases prolactin in rat pituitary cells Morning sample at rest; recent exercise or stress raises values
TSH About 0.4–4.0 mIU/L (standard reference range) Safety check: thymulin releases TSH in rat pituitary cells Add free T4 (thyroxine, the main thyroid hormone) if abnormal
hs-CRP No established target; track change from own baseline Expected to change: thymulin lowered inflammatory signaling in aged mice Not interpretable during acute illness; read alongside clinical symptoms

Qualitative markers:

  • Frequency and duration of colds and other infections
  • Recovery time after illness
  • Joint pain and stiffness, for people with inflammatory joint conditions
  • New or unusual pain sensitivity (safety signal)
  • Injection-site redness, swelling or pain

Emerging Research

  • No registered thymulin trials: A ClinicalTrials.gov search for thymulin, serum thymic factor and nonathymulin found no interventional study of the peptide as of October 2026, so no human data on longevity endpoints are expected soon.
  • Thymus regeneration (TRIIM-X): NCT04375657 tests somatropin (recombinant growth hormone), metformin and DHEA (an adrenal hormone precursor) in 85 adults (phase 2) for epigenetic age (DNA-based biological age) and thymic density. Completion date (December 2025) passed; still listed recruiting, no results. A positive result favors thymus restoration over injected thymulin; a null result weakens thymus-centered strategies.
  • Earlier thymus-regeneration results: The predecessor TRIIM study reported protective immune changes and a lower epigenetic age after one year of the same drug combination (Fahy 2019), without measuring thymulin.
  • Inflammaging and immunotherapy: Thymulin restrained age-related inflammation and improved immunotherapy response in old mice (Kanemaru 2026); human studies in older cancer patients would test whether this strengthens the case.
  • Better delivery: Nanoparticle gene delivery (da Silva 2020) and gene-therapy vectors (reviewed in Reggiani 2014) aim to overcome the native peptide’s rapid breakdown.
  • Pain analogues: A thymulin analogue lacking the low-dose pain-sensitizing effect (reviewed in Dardenne 2006) was proposed for nerve pain by its inventors, as their later review describes (Safieh-Garabedian 2019); human trials would test whether it reaches the clinic.
  • Evidence that could weaken the case: The null multiple sclerosis trial (Roullet 1989), immunosuppressive and pain-sensitizing effects in rodents, and the absence of any replication of the arthritis trials leave room for human studies to find no benefit.
  • Zinc-first strategy: Whether correcting zinc deficiency alone restores thymulin-dependent immunity in older adults remains open (Prasad 1993; Mocchegiani 2006).

Conclusion

Thymulin is a zinc-dependent hormone made by the thymus. Its activity falls from early adulthood, and that decline, together with the shrinking thymus, drives interest in replacing it to keep the immune system younger.

The human evidence is thin and old. Small placebo-controlled studies from the 1980s found improvement in rheumatoid arthritis, an effect unrelated to aging, and no benefit in multiple sclerosis; a handful of children with immune deficiencies improved without a comparison group. The findings most relevant to longevity, calmer age-related inflammation, better tumor control and preserved hormone function, come from mice and lab-grown cells and remain untested in people. Correcting zinc deficiency, which reactivates the body’s own thymulin in people short of zinc, is the only related approach with human data.

The early studies described few side effects but gave no rates, and no long-term safety data exist. Animal work raises questions about heightened pain at very low doses, dampened immune responses and stimulation of hormones from the brain’s master gland. Because thymulin is sold only as an unregulated research chemical, product purity and identity are uncertain, and it is banned in tested sport.

Much of the early clinical work came from the hormone’s discoverers, and current dosing guidance comes from businesses that sell it. For health-focused adults, the case for thymulin as a longevity tool rests mainly on biology and animal findings rather than on human outcomes.

Top - Benefits - Risks - Protocol